1, Jingfeng Medicine: pharmaceutical leading stock. On February 2, 20 18, the company announced that it had communicated with the FDA of the United States on the international multi-center phase III clinical trial of the company's anti-PD- 1 antibody SHR-12 1 0 combined with apatinib mesylate for the first-line treatment of liver cancer, which will be held in the United States, Europe and China.
2. Xianghai Pharmaceutical: pharmaceutical leading stock. Guangzhou Baiyun Mountain Pharmaceutical Group Co., Ltd. is a listed company controlled by Guangzhou Pharmaceutical Group Co., Ltd. (A shares 600332, H shares 00874), which is mainly engaged in (1) R&D, manufacturing and sales of Chinese and western medicines, chemical raw materials, natural medicines, biomedicine and intermediates of chemical raw materials; (two) the wholesale, retail and import and export business of western medicine, Chinese medicine and medical devices; (3) production and sales of R&D health products; And (4) investment in health industries such as medical services, health management, health care and old-age care.
3. China Resources Sanjiu: pharmaceutical leading stock. The profit of 20 15 in the pharmaceutical industry is expected to be 260.2 billion yuan, up 1 1.9% year-on-year, and the growth rate dropped by 0.4 percentage points year-on-year.
4. Kunyao Group: pharmaceutical leading stock. Sinopharm Co., Ltd. plans to actively develop the e-commerce industry, expand to the mobile APP "Sinopharm Online", add a "Sinopharm Online" channel, improve the public attention of Sinopharm Mall, deal with the loosening of online prescription drugs, and start preparing for the BtoC model. Previously, Sinopharm Mall, a B2B pharmaceutical e-commerce trading platform independently developed and operated by the company, was officially put into trial operation in June 20 13, and the commodities were classified into medicines, food, oral products, family planning products, medical devices, cosmeceuticals and so on.
5. Pharmaceutical leading stocks. The leading pharmaceutical outsourcing industry in China is CRO CMO Integrated Company, which was the earliest engaged in pharmaceutical R&D and production outsourcing in China. The senior management team has more than 200 authorized and pending patent achievements. Its main business is an all-round and integrated platform service for the discovery, research and development and production of small molecular chemical drugs, and provides research and development, production and supporting services for various new drugs for global pharmaceutical enterprises in the form of a whole industry chain platform; The company also provides overseas medical equipment testing and overseas precision medical R&D and production services.
Other pharmaceutical concept stocks include Haichen Pharmaceutical, Beida Pharmaceutical, Changshan Pharmaceutical, Fuan Pharmaceutical, Zhendong Pharmaceutical, Huaren Pharmaceutical and Laimei Pharmaceutical.